Innoveren Scientific Inc. · OTC:IVRN
Innoveren Scientific — Medovex — Investor Presentation (April 2015)
17 slides from Innoveren Scientific's investor presentation, Apr 27, 2015
Slide 1: April 2015
NASDAQ: MDVX April 2015
Slide 2: Disclaimer and forward-looking statements
‘Tiiedoumationcortsin din ts presse has been papuced shy forinfecaonsl peposts ands tan effect buy or sell ea sobeitson of an effete by cell any neue ee te pnp i ny mst seatey ard eay tbe un ead ype in era on ws ny ee oun of css, Sancsns wile often to nigutnd peel iwstens, Uyians of «fete pun picone
Slide 3: Medovex Corp. is an emerging leader in the aggregation of medical and healthcare technologies
xX LM ‘Medovex Corp. is an emerging leader in the aggregation of medical and healthcare technologies. Along with our DenerveX device, we are building a diversified portfolio of differentiated medical ‘products via acquisition of companies that share our vision of improving the quality of patient car
Slide 4: Medovex is an emerging leader in the aggregation of medical and healthcare technologies
‘Modover is an emerging leader in the aggregation of medical and healthcare technologies. Along with our DenerveX device, we are building through acquisition a diversified portfolio of patented ‘Medtech assets focused on improving the quality of patient care ‘hile possessing near term commercializat
Slide 5: Mission and Technology
Mission and| Technology ae DOV MEDOVEX Corporation will develop and acquire technologies that significantly | improve patient quality of care and health care economics. Initially, we have focused on management of facet joint syndrome and intra-hospital patient transport. DenerveX Device Streamline I
Slide 6: = San \
= San \ j bina Miilvied ENTRE Mma ) se smith&nephew AY BOM Merc: _i DARA BiOSciences’ Tag Mee cas | Scettific me Wie Gofunenalohaen ——
Slide 7: Growth plans for DenerveX and Streamline
rominsict MEDOVEX will achieve market growth by commercializing medical technologies that will significantly improve the quality of patient care. DenerveX Device growth plan: Facet Joint Pain Relief Therapy Complete the developmentof the DenerveX System * Gain CE marking and launch successfully in t
Slide 8: Facet Joint Syndrome
t Joi ndron + Facet oint syndrome (WS) is a condition in hich the joints in the back of the spine degenerate and subsequently cause pain. + Each joint has a rich supply of tiny nerve fibers that provide a painful stimulus shen the joint is injured or irritated. + When facet joints become wom or tom,
Slide 9: Key Market Drivers
Key Market Drivers eres Device ‘Key unmet need clinically ‘Providers and patients are looking fora more effective, longer lasting pain relief solution ‘RF ablation and JJS injections are temporary (Streamline IV Suspension System ee Za srsng sheen oh pore sno ela Td + The Streamline IV Suspension Sy
Slide 10: Temporary Treatments, Long Term Treatment, DenerveX Solution
Temporary Treatments Long Term Treatment DenerveX Solution
Slide 11: DenerveX Device features
* Consists of two procedures combined into one device * Provides for a longer lasting treatment solution i * Itis a single use medical device * Less invasive, minimal recovery time versus surgery © Offers potential savings to the health care system © Power Generator precisely matched with device for
Slide 12: Clinical background of DenerveX concept
ual Meth + The clinical efficacy of the DenerveX Device concept has been demonstrated via a study of 174 patients with three to six year follow up. * The patients were treated using a two-step procedure of capsular tissue removal and electro cautery. + The DenerveX Device from Medoves will provide a
Slide 13: Medovex has acquired Streamline
MEDOVEX corporation has acquired Streamline, a Minneapolis based medical technology company that develops and Seca Sees manufactures an intrahospital transport Far system for patient equipment that helps reduce costs and increases safety in hospitals + Supports muliple pieces of patient medical equi
Slide 14: The Problem / The Solution
The Problem The Solution ‘Traditional IV Pump and Equipment Approach Streamline TV Suspension System Approach safely? Easy yy Efficient, + Inefficient use of staff - Pulling nursing and other staff away from patients to help move equipment + Bloodstream infections related to this problem - 250,000 a
Slide 15: Unsafe
Unsafe 04 Medical _cauloment i Hesx become Likelihood of 1V line disruption bigger and more cumbersome and _—_ Limited available staff for offers significant clinical and the supporting base of equipment —_transport- right now it takes Raariicleone for ecole has not kept pace. as many as 4 people or
Slide 16: Medovex Corporation
Medovex Corporation NASDAQ: MDVX Founded by Steve Gorin (Entremed, Medicis, Medivation, MiMiedx) ) + First developmental product Co-Developed by Dr. Scott Haufe and Dr. James Andrews (world renowned orthopedic surgeon) + Experienced and proven management teem and board of directors + Strong balance
Slide 17: Medovex Corp.
] Medovex Corp. 38729 Hardee Avenue Atlanta, GA 30341 Phone: 844-633-6839 www.medovex.com Investor Contact 2 Jason Assad E Phone: 470-